Mark GrammerROCHESTER MEDICAL CORP.ROCMCOMMENTJun 06, 2007

Prefers this over Novartis

Mark Grammer

Unknown

Unlock Rating

$14.85

Stock price when the opinion was issued

biotechnologypharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Kevin Simpson

Capital Wealth Planning

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephanie Link, Chief investment strategist, Hightower

Hightower

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Mark GrammerROCHESTER MEDICAL CORP.ROCMCOMMENTJun 06, 2007

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals